All shares in the proposed offering are to be sold by Tarsus. Goldman Sachs, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

Tarsus Pharmaceuticals, Inc. announced a live webcast scheduled for May 1, 2025, at 1:30 p.m. PT to discuss its financial results for the first quarter of 2025 and provide a corporate update. The ...